Correction: Development and in vitro and ex vivo characterization of a twin nanoparticulate system to enhance ocular absorption and prolong retention of dexamethasone in the eye: from lab to pilot scale optimization
Muhammad Sarfraz, Gautam Behl, Sweta Rani, Niall O'Reilly, Peter McLoughlin, Orla O'Donovan, Alison L. Reynolds, John Lynch, Laurence Fitzhenry
TL;DR
This paper corrects a previously published study on a nanoparticle system designed to improve dexamethasone delivery to the eye.
Contribution
The correction addresses errors in the original publication to ensure accuracy and clarity.
Findings
The correction clarifies data and methodology in the original study.
It ensures the reliability of the twin nanoparticulate system's characterization and optimization.
Abstract
Correction for ‘Development and in vitro and ex vivo characterization of a twin nanoparticulate system to enhance ocular absorption and prolong retention of dexamethasone in the eye: from lab to pilot scale optimization’ by Muhammad Sarfraz et al., Nanoscale Adv., 2025, https://doi.org/10.1039/d4na01086h.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Drug Delivery Systems · Ocular Diseases and Behçet’s Syndrome · Glaucoma and retinal disorders